A systematic review and meta-analysis of the data behind current recommendations for corticosteroids for non-HIV related PCP; Knowing when you are on shaky foundations

Patil Injean1, Samantha J. Eells2,3, Hoover Wu1, Imani McElroy4, Aric Gregson4 and James A. McKinnell1,4,5,6 *

1Western University of Health Sciences, Pomona, California, USA
2Department of Epidemiology, UCLA Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles, California, USA
3Science 37, Inc., Los Angeles, California, USA
4David Geffen School of Medicine, University of California, Los Angeles, California, USA
5Division of Infectious Diseases, LA-Biomed Research Institute at Harbor-UCLA Medical Center, Los Angeles, California, USA
6Torrance Memorial Medical Center, Torrance, California, USA

Abstract

Background: Randomized trials show a mortality benefit to adjunctive corticosteroids for HIV-related Pneumocystis jiroveci pneumonia (HIV-PCP). Guidelines for non-HIV PCP (NH-PCP) recommend adjunctive corticosteroids based on expert opinion. We conducted a systematic review and meta-analysis characterizing adjunctive corticosteroids for NH-PCP.

Methods and findings: We searched MEDLINE from 1966 through 2015. Data on clinical outcomes from NH-PCP were extracted with a standardized instrument. Heterogeneity was assessed with the I2 index. Pooled odds ratios (OR) and 95% confidence interval (95% CI) were calculated using a fixed effects model. Our search yielded 5,044 abstracts, 277 articles were chosen for full review, and 6 manuscripts described outcomes in moderate to severe NH-PCP. Studies were limited by variable definitions, treatment selection bias, concomitant infections and small sample size. Individual studies reported shorter ICU stay and duration of mechanical ventilation of patients given adjunctive corticosteroids. There was no association between corticosteroids and survival in NH-PCP (OR 0.66; 95% CI: 0.38-1.15, p=0.14).

Conclusions: The literature does not support an association between adjunctive corticosteroids and survival from NH-PCP but data are limited and findings should not be considered conclusive. Further research with improved methodology is needed to better understand the role of adjunctive corticosteroids for NH-PCP.

Introduction

Research during the early AIDS epidemic fueled major advances in prevention and management of HIV-related Pneumocystis pneumonia (HIV-PCP) [1-4]. Specifically, the use of adjunctive corticosteroids for treatment of severe HIV-PCP (PaO2 <70 mmHg on room air) reduces mortality [5-7]. Non-HIV related Pneumocystis jirovecii pneumonia (NH-PCP) was previously considered a rare disease. However, with advances in immunomodulation and chemotherapeutics, NH-PCP is becoming more common. For example, NH-PCP complicates 1% of solid organ transplants and has a cumulative incidence of 0.1% per year for stem cell transplant recipients [8,9].

There are no randomized trials to evaluate the effectiveness of adjunctive corticosteroids for NH-PCP. Despite lack of randomized trials, current guidelines recommend adjunctive corticosteroids for NH-PCP [10,11]. Retrospective studies with relatively small sample size have suggested either decreased mortality [12-15] or no impact [16-19] with increasing the dosage of glucocorticoids as adjunctive treatment of moderate to severe NH-PCP. Older investigations, conducted when utilization of adjunctive glucocorticoid therapy was limited to patients with HIV-PCP, found higher mortality in NH-PCP compared to HIV-PCP [13,20-22]. More recent investigations have observed increased use of adjunctive glucocorticoids in NH-PCP, and similar mortality between HIV-PCP and NH-PCP [22-24]. With relatively limited available data to make guideline recommendations, the primary objective of this investigation was to systematically review the literature and perform a meta-analysis of available data relating to the use of adjunctive glucocorticoids in hospitalized patients with moderate to severe NH-PCP.

Methods

Search strategy and study selection: We performed a literature
search of Medline from 1966 to July 2015 and of EMBASE from 1980 to July 2015 to find published manuscripts evaluating adjunctive glucocorticoid therapy for patients with NH-PCP. We limited studies to human subjects and searched for the following terms: (Pneumocystis* [text word] OR PCP [text word] OR "Pneumocystis Infections" [MESH] OR "Pneumocystis jirovecii" [MESH] OR "Pneumonia, Pneumocystis" [MESH] OR "Pneumocystis carinii" [MESH] AND (treat* [text word] OR adjunct* [text word] OR treatment* [text word] OR steroid* [text word] OR corticosteroid* [text word] OR glucocorticoid* [text word] OR "Glucocorticoids" [MESH] OR "Adrenal Cortex Hormones" [MESH] OR "Steroids" [MESH]) NOT ("animals" [MeSH] OR "humans" [MeSH]). In addition, we examined the references of all identified articles to look for additional relevant articles. Non-English references were translated by an investigator (JM) or a native speaker whenever possible.

Abstracts from each reference from our electronic search were independently reviewed for relevance by two investigators (PI and JM) using a standardized instrument. Studies were selected for full review if they reported primary data from patients with NH-PCP treated with and without adjunctive corticosteroids. Studies that did not separate data on outcomes between patients treated with and without adjunctive corticosteroids were excluded. Reports of single case experiences were excluded on the basis of publication bias, e.g., exceptional circumstances surrounding the diagnosis, underlying conditions, or course of disease. There were no exclusions for patients with different types of immunosuppression or medical comorbidities. The intervention of interest was adjunctive corticosteroid therapy. The comparison groups were patients treated for NH-PCP with and without adjunctive corticosteroids. The outcome of interest was mortality, as defined by the study investigators. The MOOSE criteria were used to conduct this investigation and the manuscript follows PRISMA criteria [25].

**Results**

Our search yielded 5,044 references possibly related to NH-PCP. After the abstracts of all references were reviewed, 4,767 abstracts were excluded because they were not related to PCP (n=1,575), related to only H-PCP (n=1,270), were basic science or animal models studies (n=893), related to prophylaxis only (n=377), a single case report (n=374), or were only a literature review (n=278). The full manuscript for 277 references were reviewed. From the 277 investigations with data on treatment of NH-PCP, 271 references were excluded from further analysis because they did not include outcome data (n=81), did not have data on adjunctive steroid use (n=65), untranslatable by the study team (n=53), reported on HIV only (n=28), reported single cases only (n=20), outcomes were unclear (n=15), reports of PCP colonization without evidence of infection (n=7), or duplicated reports (n=2).

In the final analysis, six retrospective cohort investigations of patients treated with adjunctive corticosteroids were included [13,18] Among the six studies included in the analysis, there were 386 cases of NH-PCP. The six studies were conducted in the United States, France, Korea, and Japan. The patient population included solid organ transplantation (n=111), collagen vascular disease (n=25), rheumatoid arthritis (n=21) hematological malignancies (n=93), cancer (n=11), nonhematologic malignancies (n=29), interstitial lung disease (n=9), connective tissue disease (n=7), and other inflammatory diseases (n=50). Diagnosis of NH-PCP was based on immunofluorescent staining, microscopic examination, or PCR of the patients’ sputum, bronchoalveolar lavage fluid, or transbronchial biopsy.

The included investigations differed in their definition of adjunctive corticosteroid dose. (Table 1). The investigations defined adjunctive steroid use as; prednisone doses > 60 mg, pulse corticosteroids, high dose corticosteroids, adjunctive corticosteroids, prednisone doses ≥ 80 mg, and prednisone doses > 1 mg/kg. Nearly all patients were initially treated with TMP-SMX prior to PCP infection.

**Studies also differed in their definition of mortality. Three investigations used in hospital mortality rates, one investigation used 30day all-cause mortality, one used 30day and 90day all-cause mortality, and one used ICU mortality rates. A meta-analysis of the six studies showed treatment with adjunctive corticosteroids for NH-PCP did not have an impact on survival (OR=0.76, 95% CI 0.47-1.2;
The most common co-infections described were CMV (n=23) and Aspergillus (n=9). Patients were administered a wide range of immunosuppression at time of diagnosis. Reports of initial decline in respiratory function in patients not treated with corticosteroids was reported once [16].

Discussion

Non-HIV related Pneumocystis pneumonia is a growing problem in the United States, affecting the most vulnerable patient populations, including solid organ and stem cell transplant patients.

Our systematic review provides an important assessment of available literature on the role of adjunctive corticosteroids in the treatment of NH-PCP. We did not identify data from clinical trials. Ultimately, we found few papers that provided comparative data to assess the impact of adjunctive corticosteroids in NH-PCP. Based on our analysis of six manuscripts reporting on over 350 cases of NH-PCP, we found no association between adjunctive corticosteroids and survival in NH-PCP.

Our findings should not be considered conclusive. Despite the large number of cases, there were few investigations included in our analysis and all were retrospective in nature. Moreover, there was evidence for treatment selection bias in these investigations that was not adjusted in the original analysis and could not be adjusted for in our meta-analysis. We also caution that differences in definitions of mortality may further have introduced bias.

The effect of adjuvant corticosteroids on the duration of mechanical ventilation or ICU stay could not be assessed because only one out of six manuscripts included such intermediate outcomes data. Pareja et al found the ICU stay was shorter for patients treated with high-dose steroids (≥60 mg/day; 8.5 ± 7 days) compared to patients treated with low dose steroids or on a steroid taper (≤ 30 mg/day; 15.8 ± 8 days) (p=0.025). The duration of mechanical ventilation was also significantly reduced in the increased high - dose steroid group (6.3 ± 6 days) compared to the low dose/taper steroid group (18 ± 21 days) (p=0.047) [13]. While these data suggest potential benefit to the use of adjuvant corticosteroids, these results should be confirmed with additional studies.

There was relatively little safety data reported in these investigations. None of the manuscripts described incidence of hyperglycemia or other known side effects of corticosteroids, Moon et al, compared NH-PCP patients treated with and without adjunctive corticosteroids and found no significant differences in the rates of concomitant bacterial infection, viral infections, or respiratory failure. Future investigations should carefully assess the safety of adjunctive corticosteroids on NH-PCP.

Overall, the impact of adjunctive corticosteroids on NH-PCP remains unclear and requires further research. The currently published literature does not support a mortality benefit for adjunctive corticosteroids in NH-PCP, but the literature is limited to small, single center, retrospective cohort studies. Due to the inability to enroll an adequate number of subjects in a clinical trial, a standard prospective randomized clinical trial of NH-PCP is unlikely. Until such a trial is performed, we strongly believe that future research should make substantial changes in methodologies to provide more valuable insight. For example, a mortality endpoint, particularly a late mortality endpoint, may not be optimal in determining outcomes from NH-PCP as these patients have high risk for non-infection related deaths. Alternative outcome endpoints, including duration of ventilation, length of ICU stay, and the reporting on safety data would be valuable. Furthermore, Cox proportional hazards modeling, propensity score analysis, or instrumental variable analyses are needed to better understand outcomes from observations studies [28-30]. Until additional research using improved methodologies are published, clinicians should carefully consider the risk and benefits of adjunctive corticosteroids for NH-PCP [10,11].

Acknowledgements

PI received support from the Western University of Health Sciences Research Committee. JM received support from the NIH/NCRR/NCATS UCLA CTSI Grant Number KL2TR000122 and the Perkins Foundation. ALG received support from the NIH/NHLBI Grant Number K23HL102220.

Disclosures

None

Authorship

PI, ALG, JAM: conception, hypothesis, data review and generation, manuscript development and revision SJE: Statistical analysis, manuscript revision HW, IM: data review, manuscript revision.

References

1. Gagnon S, Boota AM, Fischl MA, Baier H, Kirksey OW, et al. (1990) Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. N Engl J Med 323: 1444-1450. [Crossref]
2. Bozzette SA, Satler FR, Chiu J, Wu AW, Gluckstein D, et al. (1990) A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 323: 1451-1457. [Crossref]
3. Montaner JS, Lawson LM, Levine N, Belzberg A, Schechter MT, et al. (1990) Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 113: 14-20. [Crossref]
4. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, et al. (2000) Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 30 Suppl 1: S5-S14. [Crossref]
5. Kaplan JE, Masur H, Holmes KK. (2002) Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 51(RR-8): 1-52. [Crossref]
6. Huang L, Morris A, Limper AH, Beck JM; ATS Pneumocystis Workshop Participants (2006) An Official ATS Workshop Summary: Recent advances and future directions in Pneumocystis pneumonia (PCP). Proc Am Thorac Soc 3: 655-664. [Crossref]
7. Briel M, Burcher HC, Boscucci R, Furrer H. (2006) Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. Cochrane Database Syst Rev 3: CD006150. [Crossref]
8. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Annaisie EJ, et al. (2010) Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001-2006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50: 1091-1100. [Crossref]
9. Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, et al. (2015) Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 50: 1101-1101. [Crossref]
10. Martin SI, Fishman JA, Practice ASTIDICO. (2013) Pneumocystis pneumonia in solid organ transplantation. Am J Transplant 13 Suppl 4: 272-279. [Crossref]
11. McKinnell JA, Cannella AP, Injean P, Gregson A. (2014) Adjunctive glucocorticoid therapy for non-HIV-related Pneumocystis carinii pneumonia (NH-PCP). Am J Transplant 14: 982-983.
12. Burke BA, Good RA (1973) Pneumocystis carinii infection. Medicine (Baltimore) 52: 23-51. [Crossref]
13. Pareja JG1, Garland R, Koziel H (1998) Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 113: 1215-1224. [Crossref]
14. Matsumura Y, Shindo Y, Iinuma Y, Yamamoto M, Shirano M, et al. (2011) Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC Infect Dis 11: 76. [Crossref]
15. Aoki Y, Iwamoto M, Kamata Y, Nagashima T, Yoshio T, et al. (2009) Prognostic indicators related to death in patients with Pneumocystis pneumonia associated with collagen vascular diseases. Rheumatol Int 29: 1327-1330. [Crossref]
16. Moon SM, Kim T, Sang H, Kim MN, Kim SH, et al. (2011) Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients. Antimicrob Agents Chemother 55: 4613-4618. [Crossref]
17. Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa J, et al. (2009) Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum 61: 305-312. [Crossref]
18. Lemiale V, Debrumetz A, Delannoy A, Alberti C, Azoulay E. (2013) Adjuvant steroid in HIV-negative patients with severe Pneumocystis pneumonia. Respir Res 14: 87. [Crossref]
19. Zahar JR1, Robin M, Azoulay E, Fieux F, Nitenberg G, et al. (2002) Pneumocystis carinii pneumonia in critically ill patients with malignancy: a descriptive study. Clin Infect Dis 35: 929-934. [Crossref]
20. Limper AH, Offord KP, Smith TF, Martin WJ, 2nd. (1989) Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. T Am Rev Respir Dis 140: 1204-1209. [Crossref]
21. Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, et al. (1984) Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 100: 663-671. [Crossref]
22. Mansharamani NG, Garland R, Delaney D, Koziel H. (2000) Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest 118: 704-711. [Crossref]
23. Nuesch R, Bellini C, Zimmerli W. (1999) Pneumocystis carinii pneumonia in human immunodeficiency virus (HIV)-positive and HIV-negative immunocompromised patients. Clin Infect Dis 29: 1519-1523. [Crossref]
24. McKinnell JA, Cannella AP, Kunz DF, Hook EW, 3rd, Moser SA, et al. (2012) Pneumocystis pneumonia in hospitalized patients: a detailed examination of symptoms, management, and outcomes in human immunodeficiency virus (HIV)-infected and HIV-uninfected persons. Transpl Infect Dis 14: 510-518. [Crossref]
25. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama 283: 2008-2012. [Crossref]
26. Bickel PJ, Hammel EA, O’connell JW (1975) Sex bias in graduate admissions: data from berkeley. Science 187: 398-404. [Crossref]
27. Pearl J. (2000) Causality: models, reasoning, and inference. Cambridge, U.K ; New York: Cambridge University Press. xvi, 384 p. p.
28. Berger ML, Mamtani M, Atkins D, Johnson ML. (2009) Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I. Value Health 12: 1044-1052. [Crossref]
29. Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U. (2009) Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part II. Value Health 12: 1062-1073. [Crossref]
30. Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML. (2009) Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoepidemiology and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II. Value Health 12: 1053-1061. [Crossref]